Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has provided an update.
MindBio Therapeutics Corp. has successfully completed a private placement and debt settlements, raising $174,783 through the issuance of common shares and settling $1,750,447 in outstanding debt. This financial maneuver is expected to support the company’s working capital and general corporate purposes, enhancing its operational stability and market positioning in the mental health treatment industry.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a biotech/biopharma company focused on developing novel treatments for mental health conditions. It is a leader in the microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio’s lead candidate is MB22001, a proprietary form of LSD for take-home microdosing, and the company is involved in psychedelic medicine development and digital therapeutics.
YTD Price Performance: -50.0%
Average Trading Volume: 104,283
Technical Sentiment Signal: Buy
See more data about MBIO stock on TipRanks’ Stock Analysis page.